27 November 2017
03 October 2017
15 May 2017
The European Commission opened a formal investigation into Aspen Pharma's pricing practices for cancer medicines. BEUC had requested the European Commission in 2016 to investigate the company’s significant price increases for some of its anticancer medicines.
Our work areas
As consumers are faced with a growing amount of information from different sources, we advocate for high quality and non-promotional information about health products.
The ageing of the population, rising healthcare costs and the economic crisis are challenging the sustainability of healthcare systems and consumers’ access to treatments.
Health scandals such as the weight-loss drug Mediator and the faulty PIP breast implants keep undermining consumers’ confidence in the safety of available health products and their oversight by the competent authorities.
- Ensure consumers have access to high quality healthcare in all EU Member States
- Guarantee consumers benefit from safe and innovative treatments
- Allow consumers to make informed choices regarding their health